Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has become the first company to have its IPO application accepted under the new fifth set of listing standards for the Sci-Tech Innovation Board, marking a significant step in the implementation of the "1+6" new policy by the China Securities Regulatory Commission [1][2] Company Overview - Tainuo Maibo was established in 2015 and is an innovative biopharmaceutical company [2] - The company's core product, Staidotamab Injection (New Taimo®), is the world's first recombinant monoclonal antibody drug against tetanus toxin, approved for market in February 2025 [2] - Tainuo Maibo has invested over 1.1 billion yuan in research and development over the past three years [2] Product Development - The company has developed several core technology platforms, including the HitmAb® high-throughput fully human monoclonal antibody research platform and the efficient antibody expression CHO-GS cell platform [2] - The core product currently under development, TNM001, is a long-acting monoclonal antibody for the prevention of RSV in healthy and high-risk infants, which is in Phase III clinical trials [2] - The company is also exploring other therapeutic areas, including pain relief (TNM009), prevention of chickenpox and shingles (TNM005), and prevention of human cytomegalovirus (TNM006) [2]
科创板第五套上市标准重启后首家！上交所受理泰诺麦博IPO申请
Zhong Guo Jing Ying Bao·2025-08-01 03:18